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a  b  s  t  r  a  c  t
Kidney  injury  following  the  administration  of iodinated  contrast  media  occurs  particularly  in  patients
with  reduced  kidney  and  cardiac  function  and  when  large  doses  of  contrast  are  used.  There  is  little  com-
pelling  evidence  that  vasodilators  and  anti-oxidants  prevent  this  injury.  Most  prevention  trials  have
employed  intravenous  volume  loading  as  a central  strategy.  However,  the success  of  this  approach
depends  upon  maintaining  euvolemia  while  producing  a vigorous  diuresis.vailable  online 12 November 2013
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A  novel  strategy  for maintaining  euvolemia  and inducing  a vigorous  diuresis  has  been  developed  using
the  RenalGuard  system.  In this  review;  the  mechanism  of  protective  action  is  reviewed.  The  trials  of the
RenalGuard  device  are  reviewed  and  future  uses  of  the  device  are  discussed.
©  2013  Published  by  Elsevier  Ltd on  behalf  of Japanese  College  of Cardiology.iuresis
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ntroduction
Contrast induced acute kidney injury was ﬁrst recognized
early 60 years ago in a case report of a patient who  received intra-
enous high osmolality contrast media [1]. Since then, changes
and the ability of contrast media to produce vasoconstriction of the
vascular supply to the kidney medulla, where oxygen delivery and
utilization are delicately balanced under normal conditions and
close to the threshold of ischemia [2]. Both the direct nephrotoxic
effect of contrast media and the vasoconstriction results in genera-n the chemical structure of contrast media and improvements
n imaging technology have resulted in the use of smaller doses
f contrast and less side effects, including a reduced incidence of
ephrotoxicity. Knowledge of the pathogenesis of the acute kidney
njury has focused on the direct nephrotoxicity of contrast media
∗ Correspondence to: UHC 2301, 1 South Prospect Street, Burlington, VT 05401,
SA.  Tel.: +1 802 847 5030; fax: +1 802 847 3607.
E-mail addresses: Richard.solomon@vtmednet.org, rsolomon@uvm.edu
914-5087/$ – see front matter © 2013 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2013.10.001tion of reactive oxygen species which further fuel the cell injury. The
knowledge of pathophysiology has given birth to a number of phar-
macologic approaches to protecting the kidney from the adverse
consequences of contrast media. These include the use of various
vasodilators (fenoldapam, theophylline, atrial natriuretic peptide,
and captopril), anti-oxidants. (N-acetylcysteine, ascorbic acid,
and sodium bicarbonate) and anti-inﬂammatory agents (statins).
However, none of these approaches have results in elimination of
the risk of contrast induced kidney injury. Furthermore, attempts
to remove contrast media from the blood with hemodialysis,
llege of Cardiology.
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emoﬁltration, and coronary sinus suction have likewise enjoyed
imited success at best despite the extra time, effort and resources
tilized.
An exception to the rather disappointing results with these
pproaches has been the use of volume expansion to minimize
ontrast induced kidney injury. Although there are few prospec-
ive and truly randomized clinical trials, the incidence of contrast
ephropathy is reduced when one uses more oral water over
ess water [3], saline over water ([4], intravenous normal saline
ver half normal saline [5], and more intravenous normal saline
ver less saline (Poseiden [6]). What these studies share in com-
on is ﬁrst, maintenance of extracellular volume (euvolemia) and
econd, an increase in urine output. Both are required for protec-
ion.
Maintenance of ECV would be predicted to ‘tone
own’  the sympathetic nervous system (SNS) and the
enin–angiotensin–aldosterone system (RAAS) reducing the
mpact of renal vasoconstriction induced by contrast media. An
ncrease in urine output might be expected to dilute the concen-
ration of contrast within the renal tubule lumen and decrease
ts contact time with renal tubule cells. Both volume expansion
nd perhaps diuresis are associated with enhanced resistance to
xidative injury [7].
Attempts  to force a diuresis with the use of mannitol or
urosemide have generally resulted in a higher incidence of kid-
ey injury with contrast media [8–10]. This is likely a result of
ailure to maintain euvolemia resulting in the activation of SNS
nd RAAS. In the PRINCE study, the use of mannitol or furosemide
as adjusted based upon the hemodynamic characteristics of the
atient. In that study, the greater the urine output the lower the
hange in serum creatinine at 48 h [11] (see Fig. 1). There was no
ontrast induced acute kidney injury in patients who  achieved a
rine output >150 ml/h. To achieve no change in creatinine at all,
 urine volume in excess of 250 ml/min was required. In the “real
orld” of a busy clinical service, this is extremely difﬁcult to achieve
ithout risking volume depletion.
ig. 2. The protocol for use of RenalGuard in patients undergoing angiography. Followi
atient receives an initial volume bolus (250 ml  of normal saline over 20–30 min) follow
rst  injection of contrast when urine output exceeds 300 ml/h. The matching of urine outpuFig. 1. Data from the PRINCE study showing the point at which no change in serum
creatinine was  predicted by the regression curve.
Recently, a strategy to achieve a high urine output while main-
taining euvolemia has been developed by PLC Medical Systems
(Milford, Massachesetts) with their RenalGuard System. In a sim-
ple conceptual form, this is a urinary collection bag that is hung on
a digital scale that in turn drives a high volume ﬂuid pump. Each
drop of urine entering the collection bag results in an equal volume
of saline infused back into the patient. The infusion rate is adjusted
second by second in response to changes in urine output, thus pre-
venting a net loss or gain of ﬂuid from the body. By administering a
small bolus of ﬂuid initially (∼3 ml/kg) and initiating diuresis with
a small dose of furosemide (0.25 mg/kg), urine output increases
to 500–600 ml/min in about 60 min  and can be sustained for 6 h
usually without additional diuretic administration (see Fig. 2).
The  ﬁrst therapeutic use of this system was  in patients under-
going coronary angiography with a goal to preventing contrast
induced acute kidney injury. The results of those trials are discussed
below.RenalGuard trials
A  similar protocol was  used in all trials. As soon as the Foley
catheter was placed the RenalGuard system was  turned on and a
ng placement of a Foley catheter and engagement of the RenalGuard device, the
ed by furosemide 0.25 mg/kg administered intravenously. The patient is given the
t with intravenous ﬂuid input continues for 4 h after the completion of angiography.
f Cardiology 63 (2014) 9–13 11
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Fig. 3. Actual urine outputs from the REMEDIAL II study. Note the wide error barsR. Solomon / Journal o
uid bolus of ∼250 ml  of normal saline (reduced to 150 ml  in those
ith LV dysfunction) was administered. Prior to being brought to
he catheterization laboratory, a priming dose of furosemide was
dministered (0.25 mg/kg). Injection of contrast was delayed until
he device indicated an instantaneous urine ﬂow rate of >300 ml/h
average ∼45 min). Urine ﬂow rate is maintained at >300 ml/h for
 h with additional doses of furosemide if necessary (Fig. 2).
ilot study (US) [12]
The  ﬁrst-in-man study enrolled 23 patients with a mean eGFR
f 41 ml/min who underwent coronary angiography with a mean
f 184 ml  of contrast. Diabetes was present in 35% of patients. They
eceived an average of 39 mg  of furosemide during the time the
ystem was running. The system matched IV input to urine output
ithin 0.1% over the 7.5 h that the device was in use. CIN (≥25% or
.5 mg/dl within 48–60 h) occurred in 9% of patients. There were no
lectrolyte abnormalities detected. There were no reported adverse
vents. This pilot study concluded that the device was safe and
atched urine output with intravenous input exceptionally well.
YTHOS  (Italy) [13]
Patients  (n = 176) with baseline eGFR < 60 ml/min/1.73 m2 were
andomized to IV ﬂuids (1 ml/kg/h of NS 12 h before to 12 h
fter angiography) vs RenalGuard. (250 ml  NS loading, furosemide
.5 mg/kg, and matched ﬂuid × 4 h post angiography). The primary
ndpoint was CIN deﬁned as a ≥25% relative rise or ≥0.5 mg/dl
bsolute rise in serum creatinine at 72 h.
The  control and experimental groups were equally matched
or baseline kidney function (41 vs 38 ml/min respectively), car-
iac function (LVEF 52% vs 51% respectively), volume of contrast
sed (158 vs 181 ml  respectively), presence of diabetes (35% vs 44%
espectively) as well as age, gender, and use of medications. PCI was
erformed in 59% of the patients.
The primary endpoint was observed in 18% of control and
.6% of RenalGuard treated patients (p = 0.005). The difference in
rimary endpoint was seen in both elective and urgent patients
10% vs 4% and 32% vs 5% respectively). After adjusting for Mehran
isk score, the relative risk of CIN in the RenalGuard group was
.29 (95% CI: 0.1–0.83, p = 0.023).
The  major in-hospital event was CHF occurring in 12% of con-
rols and 6% of RenalGuard treated patients (p = 0.15). There was no
ifference in the need for dialysis (control 4% vs RenalGuard 1.1%,
 = 0.29). Overall in-hospital adverse event rate based upon ITT was
0% in control vs 8% in RenalGuard treated patients (p = 0.02).
Two points of interest regarding this study are worth mention-
ng. The control group put out ∼3100 ml  urine during the 24 h
eriod. A similar volume of urine was excreted by the RenalGuard
roup during only 6 h of therapy. The control group received only
1700 ml  of saline during the 24 h. Therefore, these patients were
n negative ﬂuid balance, a situation that might contribute to acute
idney injury.
EMEDIAL II (Italy) [14]
Patients  (n = 292) with baseline eGFR ≤ 30 ml/min/1.73 m2 or a
ehran risk score of ≥11 were randomized to NAC (total dose
6 g) and bicarbonate (1.5 mEq/kg) or NAC (1.5 g at procedure)
nd RenalGuard (250 ml  NS, furosemide 0.25 mg/kg, and matched
uid input × 4 h post angiography). The primary endpoint was  a
0.3 mg/dl absolute creatinine increase 48 h after contrast expo-
ure. Most patients underwent coronary angiography (∼90%) with
CI (55%) but some underwent peripheral angiography.indicating the variability in patients’ response to RenalGuard. To maintain urine
volumes >300 ml/min for the entire duration of RenalGuard use, additional doses of
furosemide may be necessary.
The control and RenalGuard groups were equally matched for
baseline kidney function (32 vs 32 ml/min respectively), cardiac
function (LVEF% 48% vs 46% respectively), volume of contrast used
(145 vs 135 ml  respectively), presence of diabetes (71% vs 69%
respectively) as well as age, gender, and use of medications.
The  primary endpoint of CIN was  reduced in the RenalGuard
group by 53%. Using a deﬁnition of contrast induced acute kidney
injury of ≥25% increase in creatinine at 48 h, RenalGuard performed
better than control (2.7% vs 13% respectively). Of note, 50% of the
patients in the RenalGuard group who developed CIN had urine
ﬂow rates <300 ml/h during therapy. Fig. 3 shows the degree of
variability in the urine ﬂow rates and highlights the importance
of having a system that automatically adjusts to changing urine
ﬂow rates. The severity of AKI using AKIN criteria was  worse in the
control group and the need for renal replacement therapy occurred
in 5 patients in the control and only 1 patient in the RenalGuard
group.
At 1 month, MACE and mortality were similar in the two  groups
while the use of dialysis was  higher in the control group compared
to the RenalGuard group (4.8% vs 0.7%, p = 0.031). Four patients (3
RenalGuard and 1 Control) developed CHF immediately following
the coronary intervention. No other adverse events were recorded.
Modena (Italy) [15]
100  consecutive patients with eGFR ≤ 30 or Mehran risk score
≥11 were enrolled in CIN prevention protocols involving hemoﬁl-
tration, NAC and bicarbonate, or RenalGuard.
CIN (0.3 mg/dl creatinine increase within 48 h) occurred in 31%
of hemoﬁltration, 25% of NAC/Bicarbonate, and only 15% of Renal-
Guard patients (p = 0.288). No patients in the RenalGuard group
required in-hospital dialysis while 20% of patients who  received
hemoﬁltration and 6% of NAC/bicarbonate patients did so. In-
hospital MACE was  also less frequent in the RenalGuard group
compared to hemoﬁltration or NAC/bicarbonate groups (6% vs 37%
vs 12% respectively). At 6 months, mortality was 26% (hemoﬁl-
tration) vs 6% (NAC/bicarbonate) vs 0% (RenalGuard) (p = 0.002).
Although this is not a randomized trial and has been presented in
abstract only, the results support the randomized trials cited above.
Synergy (US)
A  US pivotal trial is in progress. The primary efﬁcacy endpoint
is the occurrence of CIN, deﬁned as a ≥25% or ≥0.5 mg/dl rise
in creatinine within 72 h post angiography. Patients scheduled to
receive at least 75 ml  of contrast during angiography and with an
eGFR 15–45 ml/min or 46–60 ml/min with two additional CIN risk
12 R. Solomon / Journal of Cardiology 63 (2014) 9–13
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eduction in the incidence of CIN.
actors are eligible. Excluded are patients with: STEMI within 48 h,
lass 3 or 4 heart failure or LVEF <35%, acute kidney injury, mod-
rate to severe anemia (hct < 27%), hemodynamic instability, or
evere respiratory distress. The study will compare use of the Renal-
uard + NAC against saline (3 ml/kg bolus, 1.5 ml/kg during and 4 h
fter angiography) plus NAC. The NAC dosing protocol will be deter-
ined at each site. The study expects to enroll a minimum of 326
atients to show an absolute difference in the incidence of CIN of
0% (15% control vs 5% RenalGuard). Secondary endpoints include
0-day mortality, MI,  Stroke, heart failure, and dialysis. The study
esign allows for an interim analysis at 163 patients by an indepen-
ent IDMC. They will tell the sponsor how many more patients are
eeded to achieve statistical signiﬁcance. The trial design allows
or a maximum of 652 patients.
ummary
These trials, now involving over 250 patients who have been
reated with the RenalGuard device, reveal a number of important
ndings. First, patients with severely depressed kidney function
an be made to safely excrete large volumes of urine without
eveloping electrolyte disorders or critical shifts in extracellular
olume. This is somewhat surprising as these very patients are
ften labeled as ‘diuretic resistant’. What the RenalGuard device
ighlights is that avoidance of volume depletion removes the brake
n diuretic-induced natriuresis. Since the patients did not experi-
nce any change in serum sodium during the treatment period,
hey must be excreting sodium at the same rate as they are receiv-
ng it. Few patients developed evidence of congestion during the
rocedure and in some reports the incidence of congestion was
igher in the control protocol. The development of symptoms of
ongestive heart failure is reported in all trials of CIN prevention
hat involve volume expansion. The RenalGuard system uses a min-
mal volume expansion protocol (3 ml/kg over 20–30 min). This is
onsiderably less than the volume given in trials of saline or bicar-
onate (∼9–10 ml/kg over 4–6 h). It is possible that the 3 ml/kg
iven in the short time interval could exacerbate existing asymp-
omatic left ventricular failure.
Second, inducing a high urine output while maintaining euv-
lemia diminishes the nephrotoxic impact of contrast media.
ig. 4 shows in graphic form the results from the randomized
ontrolled trials. How this occurs is speculative. Faster transit
hrough the tubule, decreased luminal concentration, or activation
f anti-oxidative mechanisms may  all play a role. Importantly, the
rocedure takes advantage of natural, endogenous mechanisms of
rotection from ischemia with minimal pharmacologic assistance. II. In both trials, use of RenalGuard was  associated with a statistically signiﬁcant
Doses  of intravenous furosemide averaged 14–39 mg in the tri-
als.
Patients can be ready for a cardiac intervention in an average of
45 min  consistent with door-to-balloon time goals. As with any new
therapy, initial enthusiasm based upon efﬁcacy is usually tempered
as more experience brings to light more side effects. In the case of
RenalGuard, use of a Foley catheter, administration of normal saline
intravenously, and intravenous furosemide are already widely used
in therapeutics so the prospect of additional, unknown side effects
seems small.
The  future
The  prevention of kidney injury from other nephrotoxins,
in  particular chemotherapeutic agents such as cisplatin and
methotrexate, would be likely targets for additional studies. Cur-
rent guidelines for administering these agents recommend volume
loading and increasing urine output to reduce nephrotoxicity [16].
Hypercalcemia represents another potential nephrotoxic insult
where vigorous diuresis has been used for decades as a ther-
apy [17]. Patients undergoing kidney transplantation, particularly
living donor transplants, are often polyuric for many days. Care-
ful monitoring of urine output and replacement with IV ﬂuid is
necessary to prevent volume depletion. The RenalGuard system
accomplishes this automatically and could prevent inadvertent vol-
ume  depletion and reduce staff work. A similar situation occurs
during a post obstructive diuresis. Use of the RenalGuard to prevent
volume depletion would enhance patient safety while minimizing
staff efforts. In all these situations involving a high hourly rate of
urine excretion, it is necessary to have a Foley catheter in place.
Although the use of a Foley catheter may  be uncomfortable for some
patients, the majority of patients ﬁnd this preferable to having to
void every 30–60 min. For patients undergoing cardiac catheteriza-
tion via a femoral artery approach, bedrest for 4–6 h is a standard
approach making use of a Foley catheter a convenience. These and
potentially other uses of forced diuresis should be studied using the
RenalGuard system.
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